Dr. Randal K Hughes, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7747 W Jefferson Blvd, Suite A, Fort Wayne, IN 46804 Phone: 260-459-8444 Fax: 260-459-8443 |
News Archive
According to researchers at the National Heart, Lung, and Blood Institute (NHLBI), increasing the dose of niacin to patients with heart disease who are already taking a cholesterol-lowering statin does nothing extra to prevent heart attacks and strokes. Approximately one out of seven Americans have high blood cholesterol, a main risk factor in heart disease, which kills some 800,000 people in the United States annually.
BRIM Biotechnology, Inc., announced today that it has entered a Collaboration, Option and License Agreement with Janssen Pharmaceutica N.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.
Research indicates that neurodegeneration in the cholinergic system in the brain is a major contributor to cognitive decline in patients with Parkinson's disease.
Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and commissions and expenses, will be approximately $32.8 million.
› Verified 1 days ago